One‐year clinical outcome with a novel self‐expanding transcatheter heart valve

OBJECTIVES: To evaluate 1‐year outcome using the ACURATE neo (Symetis S.A., a Boston Scientific Company, Ecublens, Switzerland) according to the updated Valve Academic Research Consortium (VARC‐2) with emphasis on the composite endpoints “clinical efficacy after 30 days” and “time‐related valve safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Pellegrini, Costanza, Rheude, Tobias, Trenkwalder, Teresa, Mayr, N. Patrick, Michel, Jonathan, Kastrati, Adnan, Schunkert, Heribert, Kasel, Albert M., Joner, Michael, Hengstenberg, Christian, Husser, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
VALVULAR AND STRUCTURAL HEART DISEASES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899934/
https://www.ncbi.nlm.nih.gov/pubmed/30801906
http://dx.doi.org/10.1002/ccd.28144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899934/
https://www.ncbi.nlm.nih.gov/pubmed/30801906
http://dx.doi.org/10.1002/ccd.28144

Ejemplares similares